Results 231 to 240 of about 104,843 (319)

Altered renal and platelet arachidonic acid metabolism in cirrhosis

open access: bronze, 1986
Giacomo Laffi   +7 more
openalex   +1 more source

Intestinal Dysmotility and Associated Disorders in Intestinal Muscle of Methylglyoxal‐Treated Mice

open access: yesNeurogastroenterology &Motility, EarlyView.
In patients undergoing long‐term peritoneal dialysis, intestinal transit capacity is often impaired, though the underlying mechanism remains unclear. Using a mouse model, we identified inflammation and impairment of interstitial cells of Cajal (ICC) in intestinal smooth muscle as potential contributors to this reduced transit capacity.
Yuki Yamakawa   +2 more
wiley   +1 more source

Insulin resistance, overweight, and obesity in apheresis donors: A call to reevaluate their eligibility—A prospective cohort study

open access: yesTransfusion, EarlyView.
Abstract Background Apheresis procedures and the infusion of acid‐citrate‐dextrose induce metabolic alterations that may influence glucose metabolism. Although insulin resistance (IR), overweight, and obesity are not exclusion criteria for blood donation, their impact during apheresis procedure and on post‐donation metabolic responses remains ...
Edgar Barrientos‐Galeana   +14 more
wiley   +1 more source

Effects of acute selective cyclooxygenase‐2 inhibition on skeletal muscle microvascular oxygenation and exercise tolerance

open access: yesExperimental Physiology, EarlyView.
Abstract The cyclooxygenase (COX) pathway regulates vascular tone and, therefore, local O2 delivery‐utilization matching. The two main isoforms, COX‐1 and COX‐2, may promote opposing effects on contracting muscle O2 transport in health by inducing vasoconstriction and vasodilatation, respectively.
Michael D. Belbis   +9 more
wiley   +1 more source

LIBX‐A401: A Novel Selective Inhibitor of Acyl‐CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode

open access: yesAngewandte Chemie, Volume 137, Issue 19, May 5, 2025.
The discovery of LIBX‐A401, a potent and selective ACSL4 inhibitor derived from rosiglitazone is reported. HDX‐MS reveals that LIBX‐A401 stabilizes the ACSL4 C‐terminus and alters the fatty acid (FA) gate domain. Consistently, photoaffinity labeling, molecular dynamics, and mutagenesis identify key binding residues within the FA pocket.
Darius Mazhari Dorooee   +19 more
wiley   +2 more sources

Home - About - Disclaimer - Privacy